GeneBio Systems
SLAMF7 Polyclonal Antibody
SLAMF7 Polyclonal Antibody
SKU:E-AB-52145
Couldn't load pickup availability
Size: 200μL
Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.
Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.
Exp date: 12 months
Category ID_II: Primary Antibodies
Category ID_III: Polyclonal Antibodies
Abbreviation: SLAMF7
Target Synonym: 19A;19A24 protein;CD 319;CD2 like receptor activating cytotoxic cells;CD2 subset 1;CD319 ;CD319 antigen;CRACC ;CS1 ;Membrane protein FOAP 12;Novel Ly9 ;Novel LY9 (lymphocyte antigen 9) like protein;Protein 19A;SLAM family member 7;SLAMF 7
Research Areas: Immunology
Conjugation: Unconjugated
Host: Rabbit
Species reactivity: Human
Application: IHC
Isotype: IgG
Clonality: Polyclonal
Clone NO.:
UNIProt ID: Q9NQ25
Accession:
Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform1mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).
Concentration: 2.5 mg/mL
Immunogen: Fusion protein of human SLAMF7
Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4
Purification method: Antigen affinity purification
Dilution: IHC 1:30-1:150
Calculated MW:
ObservedMW:
